Literature DB >> 22037227

p53, a novel regulator of lipid metabolism pathways.

Ido Goldstein1, Osnat Ezra, Noa Rivlin, Alina Molchadsky, Shalom Madar, Naomi Goldfinger, Varda Rotter.   

Abstract

BACKGROUND & AIMS: In this study we aimed at characterizing the regulation of hepatic metabolic pathways by the p53 transcription factor.
METHODS: Analysis of gene expression following alteration of p53 status in several human- and mouse-derived cells using microarray analysis, quantitative real-time PCR, chromatin immunoprecipitation, and reporter gene assays. A functional assay was performed to determine lipid transfer activity.
RESULTS: We identified a novel role for the p53 protein in regulating lipid and lipoprotein metabolism, a process not yet conceived as related to p53, which is known mainly for its tumor suppressive functions. We revealed a group of 341 genes whose expression was induced by p53 in the liver-derived cell line HepG2. Twenty of these genes encode proteins involved in many aspects of lipid homeostasis. The mode of regulation of three representative genes (Pltp, Abca12, and Cel) was further characterized. In addition to HepG2, the genes were induced following activation of p53 in human primary hepatic cells isolated from liver donors. p53-dependent regulation of these genes was evident in other cell types namely Hep3B cells, mouse hepatocytes, and fibroblasts. Furthermore, p53 was found to bind to the genes' promoters in designated p53 responsive elements and thereby increase transcription. Importantly, p53 augmented the activity of secreted PLTP, which plays a major role in lipoprotein biology and atherosclerosis pathology.
CONCLUSIONS: These findings expose another facet of p53 functions unrelated to tumor suppression and render it a novel regulator of hepatic lipid metabolism and consequently of systemic lipid homeostasis and atherosclerosis development.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037227     DOI: 10.1016/j.jhep.2011.08.022

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  42 in total

1.  p53-mediated regulation of bile acid disposition attenuates cholic acid-induced cholestasis in mice.

Authors:  Pan Chen; Dongshun Li; Yixin Chen; Jiahong Sun; Kaili Fu; Lihuan Guan; Huizhen Zhang; Yiming Jiang; Xi Li; Xuezhen Zeng; Xiao Chen; Min Huang; Huichang Bi
Journal:  Br J Pharmacol       Date:  2017-10-22       Impact factor: 8.739

2.  TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular stress and the subsequent induction of the unfolded protein response.

Authors:  Roi Isaac; Ido Goldstein; Noa Furth; Neta Zilber; Sarina Streim; Sigalit Boura-Halfon; Eytan Elhanany; Varda Rotter; Moshe Oren; Yehiel Zick
Journal:  Cell Death Differ       Date:  2016-10-14       Impact factor: 15.828

3.  p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.

Authors:  Sung-Hwan Moon; Chun-Hao Huang; Shauna L Houlihan; Kausik Regunath; William A Freed-Pastor; John P Morris; Darjus F Tschaharganeh; Edward R Kastenhuber; Anthony M Barsotti; Rachel Culp-Hill; Wen Xue; Yu-Jui Ho; Timour Baslan; Xiang Li; Allison Mayle; Elisa de Stanchina; Lars Zender; David R Tong; Angelo D'Alessandro; Scott W Lowe; Carol Prives
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

Review 4.  The Organelle-Specific Regulations and Epigenetic Regulators in Ferroptosis.

Authors:  Yixuan Zhang; Mingrui Li; Yiming Guo; Shuang Liu; Yongguang Tao
Journal:  Front Pharmacol       Date:  2022-06-17       Impact factor: 5.988

Review 5.  The role of the p53 tumor suppressor in metabolism and diabetes.

Authors:  Che-Pei Kung; Maureen E Murphy
Journal:  J Endocrinol       Date:  2016-09-09       Impact factor: 4.286

6.  Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes.

Authors:  Stephan Singer; Ruiying Zhao; Anthony M Barsotti; Anette Ouwehand; Mina Fazollahi; Elias Coutavas; Kai Breuhahn; Olaf Neumann; Thomas Longerich; Tobias Pusterla; Maureen A Powers; Keith M Giles; Peter J Leedman; Jochen Hess; David Grunwald; Harmen J Bussemaker; Robert H Singer; Peter Schirmacher; Carol Prives
Journal:  Mol Cell       Date:  2012-10-24       Impact factor: 17.970

7.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Fang Xu; Xiaohao Shi; Yue Wang; Linhong Deng
Journal:  Cytotechnology       Date:  2014-07-08       Impact factor: 2.058

Review 8.  Transcriptional and Chromatin Regulation during Fasting - The Genomic Era.

Authors:  Ido Goldstein; Gordon L Hager
Journal:  Trends Endocrinol Metab       Date:  2015-10-29       Impact factor: 12.015

9.  Phospho-ΔNp63α/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistance.

Authors:  Yiping Huang; Lauren N Bell; Jun Okamura; Myoung Soo Kim; Robert P Mohney; Rafael Guerrero-Preston; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2012-09-05       Impact factor: 4.534

10.  The complexity of p53-mediated metabolic regulation in tumor suppression.

Authors:  Yanqing Liu; Wei Gu
Journal:  Semin Cancer Biol       Date:  2021-03-27       Impact factor: 17.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.